Evaluation of berberine pellet effect on clinical recovery time in COVID-19 outpatients: A pilot clinical trial
Description
CONCLUSION: Berberine (300 mg, TID, two weeks) is ineffective in treating COVID-19. More research with a larger sample size is needed to investigate different berberine dosages in other pharmaceutical formulations.
